Go Deep
Krystal Biotech, Inc.
Krystal Biotech, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,536 | 41.6 | 7.22 | 0.01 | 32,029.68 |
| Oct 2026 | 18,419 | 41.6 | 7.23 | 0.01 | 31,792.56 |
| Oct 2026 | 18,685 | 40.2 | 6.99 | 0.01 | 30,585.26 |
| Oct 2026 | 18,455 | 41.4 | 7.20 | 0.01 | 31,398.19 |
| Oct 2026 | 18,473 | 40.1 | 7.19 | 0.01 | 31,337.14 |
| Oct 2026 | 18,795 | 39.7 | 6.89 | 0.01 | 29,984.86 |
| Oct 2026 | 18,707 | 40.1 | 6.97 | 0.01 | 30,364.95 |
| Oct 2026 | 18,582 | 40.8 | 7.09 | 0.01 | 30,855.15 |
| Oct 2026 | 18,660 | 40.4 | 7.02 | 0.01 | 30,471.54 |
| Oct 2026 | 18,710 | 40.1 | 6.97 | 0.01 | 30,217.33 |
Krystal Biotech, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 119,222,000.0 | 116,357,000.0 | 107,105,000.0 | 97,800,000.0 |
| Net Profit | 54,768,000.0 | 55,932,000.0 | 51,400,000.0 | 79,365,000.0 |
| EPS | 1.9 | 1.9 | 1.8 | 2.7 |
Krystal Biotech, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 389,130,000.0 | 290,515,000.0 | 50,699,000.0 | 0.0 | — |
| Net Profit | 204,831,000.0 | 89,159,000.0 | 10,932,000.0 | -139,975,000.0 | — |
| EPS | 7.1 | 3.1 | 0.4 | -5.5 | — |
Krystal Biotech, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,333,794,000.0 | 1,055,838,000.0 | 818,355,000.0 | 558,450,000.0 | — |
| Total Liabilities | 114,234,000.0 | 109,458,000.0 | 39,714,000.0 | 36,219,000.0 | — |
| Total Equity | 1,219,560,000.0 | 946,380,000.0 | 778,641,000.0 | 522,231,000.0 | — |
Owes vs Owns
Krystal Biotech, Inc. owed $0.09 for every $1 it owned in Jun 2026, up from $0.06 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.09× | 0.09× | 0.10× | 0.05× | 0.06× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Krystal Biotech, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 62.1%Receivables 9.6%Inventory 3.0%Fixed assets (tangible) 11.8%Long-term investments 9.6%Other assets 3.9%
How it's funded — Dec 2025
Long-term debt 0.6%Other liabilities 7.6%Shareholders' equity 91.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 827.8 | 597.5 | 532.2 | 379.2 |
| Receivables | 127.4 | 104.7 | 42.0 | 0.0 |
| Inventory | 40.5 | 26.5 | 7.0 | 0.0 |
| Fixed assets (tangible) | 158.0 | 161.4 | 168.2 | 169.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 128.1 | 152.1 | 62.0 | 4.6 |
| Other assets | 52.0 | 13.5 | 7.0 | 4.9 |
| Liabilities & equity | ||||
| Short-term debt | 1.8 | 1.2 | 1.5 | 1.6 |
| Long-term debt | 7.6 | 6.0 | 6.6 | 7.4 |
| Payables | 3.2 | 5.0 | 4.1 | 4.0 |
| Other liabilities | 101.7 | 97.2 | 27.5 | 23.3 |
| Shareholders' equity | 1,219.6 | 946.4 | 778.6 | 522.2 |
| Net tangible assets | 1,219.6 | 946.4 | 778.6 | 522.2 |
Krystal Biotech, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 200,865,000.0 | 123,420,000.0 | -88,804,000.0 | -100,569,000.0 | — |
| Investing Activities | -58,417,000.0 | -163,439,000.0 | 82,638,000.0 | -114,083,000.0 | — |
| Financing Activities | 8,705,000.0 | 27,014,000.0 | 202,750,000.0 | 35,347,000.0 | — |